Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
301 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Switzerland 66
302 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 63
303 Apheresis Allogeneic T -Cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 45
304 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Croatia 57
305 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 40
306 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Kazachstan 8
307 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 65
308 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 66
309 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 68
310 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 65
311 Apheresis Allogeneic Diffuse Large B-Cell Lymphoma Hematology 2026 Standard Therapy Germany 63
312 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 66
313 Apheresis Allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 44
314 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 57
315 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy UK 62
316 Apheresis Allogeneic Aplastic Anemia Hematology 2026 Standard Therapy Poland 22
317 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 72
318 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 68
319 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Belgium 63
320 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 47
321 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 51
322 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 70
323 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Bulgaria 28
324 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
325 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 73
326 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 69
327 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 10
328 Apheresis Allogeneic T-cell non-Hodgkin lymphoma / NK Hematology 2026 Standard Therapy Poland 19
329 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Belgium 48
330 Apheresis Allogeneic Essential Thrombocythemia Hematology 2026 Standard Therapy USA 59
331 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Ukraine 58
332 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 72
333 Apheresis Allogeneic B-ALL B-cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Netherlands 71
334 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Poland 59
335 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 67
336 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 67
337 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 37
338 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 66
339 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 48
340 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 15
341 Apheresis Allogeneic Chronic Myelogenous Leukemia Hematology 2026 Standard Therapy USA 45
342 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 61
343 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 43
344 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 64
345 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 29
346 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 69
347 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 61
348 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 67
349 Apheresis Allogeneic Orofacial Myofunctional Disorders (OMDS); Primary Myelofibrosis (PMF) to secondary Acute Myeloid Leukemia (AML) Hematology 2026 Standard Therapy Germany 36
350 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy USA 66
351 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 66
352 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 57
353 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy India 51
354 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 25
355 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 35
356 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Finland 40
357 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2026 Standard Therapy USA 49
358 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 66
359 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 67
360 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 50
361 Apheresis Allogeneic T Lymphblastic Leukemia/Lymphoma Hematology 2026 Standard Therapy Canada 43
362 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy France 74
363 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 67
364 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 59
365 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 44
366 Apheresis Allogeneic Multiple Myeloma Hematology 2026 Standard Therapy Poland 56
367 Apheresis Autologous Anaplastic T Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Portugal 23
368 Apheresis Autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 66
369 Apheresis Allogeneic T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 55
370 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
371 Apheresis Autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 53
372 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 56
373 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 69
374 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Lithuania 60
375 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 75
376 Apheresis Allogeneic Myelofibrosis Hematology 2026 Standard Therapy Poland 58
377 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 74
378 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 69
379 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 70
380 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 25
381 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Sweden 65
382 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Spain 72
383 Apheresis Allogeneic Lymphoma Burkitt Histiocytic Sarcoma Hematology 2026 Standard Therapy Greece 12
384 Apheresis Allogeneic Acute Myelogenous Leukaemia Hematology 2026 Standard Therapy France 69
385 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2026 Standard Therapy USA 69
386 Apheresis Allogeneic Acute Myeloid Leukemia FLT3-ITD positive Hematology 2026 Standard Therapy Romania 11
387 Apheresis Allogeneic Myelofibrosis (MF) Hematology 2026 Standard Therapy Lithuania 67
388 Apheresis Allogeneic X-ALD (E 71.3) Hematology 2026 Standard Therapy Czechia 5
389 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 73
390 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 36
391 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 56
392 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 53
393 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Ukraine 39
394 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 24
395 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 62
396 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 70
397 Apheresis Allogeneic Other Malignancy Hematology 2026 Standard Therapy USA 71
398 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 62
399 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 59
400 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 70
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?